ZLNA ZELLUNA ASA

Zelluna ASA – Key information relating to subsequent offering

Zelluna ASA – Key information relating to subsequent offering

Reference is made to the stock exchange announcement made by Zelluna ASA (the "Company") on 3 November 2025 regarding the allocation of 5,500,000 new shares in the Company in a private placement (the "Private Placement"), the allocation of 315,639 new shares in a retail offering via the PrimaryBid platform (the "PrimaryBid Offering"), and a potential subsequent repair offering of up to 800,000 new shares at the same subscription price as in the Private Placement and the PrimaryBid Offering (the "Subsequent Offering"). The Subsequent Offering will, subject to applicable securities law, be directed towards existing shareholders in the Company as of 3 November 2025, as registered in the Company's register of shareholders with Euronext Securities Oslo on 5 November 2025, who (i) were not included in the pre-sounding phase of the Private Placement; (ii) were not allocated shares in the Private Placement, and (iii) are not resident in a jurisdiction where such offering would be unlawful or, would (in jurisdictions other than Norway) require a prospectus, filing registration or similar action.

The following key information is provided with respect to the Subsequent Offering:

Date on which the terms and conditions of the Subsequent Offering were announced: 3 November 2025

Last day including right: 3 November 2025

Ex-date: 4 November 2025

Record date: 5 November 2025

Date of approval: On or about 25 November 2025 (date of extraordinary general meeting)

Maximum number of new shares: 800,000

Subscription price: NOK 10 per share

Shall the rights be listed: No

Other information: The Subsequent Offering is subject to, inter alia, completion of the Private Placement, approval by the board of directors and an extraordinary general meeting of the Company, and the publication of a prospectus. Whether or not the Subsequent Offering will ultimately take place, will depend inter alia on the development of the price of the shares in the Company after completion of the Private Placement, and the Company reserves the right in its sole discretion to not conduct or to cancel the Subsequent Offering.

This information is published in accordance with the requirements of the Continuing Obligations for Euronext Oslo Børs.



 



EN
03/11/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ZELLUNA ASA

 PRESS RELEASE

Zelluna ASA – Mandatory notification of trade

Zelluna ASA – Mandatory notification of trade Oslo, Norway, 27 March 2026 - Anders Tuv, Managing Director in Radforsk Invest, and Chairperson and co-founder of Zelluna ASA (Zelluna), has today entered into an agreement with Radforsk Investeringsstiftelse (Radforsk) pursuant to which Mr. Tuv has been granted options (the Options) to acquire up to 200,000 shares held by Radforsk in Zelluna. Each Option provides a right to acquire one share in Zelluna from Radforsk at an exercise price of NOK 18.5 per share (subject to customary adjustments). The Options are immediately vested and may be exer...

 PRESS RELEASE

Zelluna to host Capital Markets Update 2026

Zelluna to host Capital Markets Update 2026 Oslo, Norway – 26 March 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, invites investors, analysts and other stakeholders to attend its Capital Markets Update on 14 April 2026 (11:30–13:00 CET). At the event the company will present progress on its TCR-NK off-the-shelf cell therapy platform and ongoing clinical activities, including perspectives on early clinical data and recent developments in the cell therapy field. The ...

 PRESS RELEASE

Zelluna ASA [ZLNA]: Notice of Annual General Meeting on 23 April 2026

Zelluna ASA [ZLNA]: Notice of Annual General Meeting on 23 April 2026 Oslo, 26 March 2026 - The Board of Directors hereby calls for the Annual General Meeting of Zelluna ASA at 09:00 CEST on 23 April 2026.  The General Meeting will be held electronically and all documents related to the Annual General Meeting are available at the Company’s website at  For further information, please contact: Anders Tuv, Chairman of the BoardEmail: Phone: Namir Hassan, Chief Executive OfficerEmail: Phone: Geir Christian Melen, Chief Financial OfficerEmail: Phone:   Attachments ...

 PRESS RELEASE

Zelluna ASA [ZLNA]: Annual Report 2025

Zelluna ASA [ZLNA]: Annual Report 2025 Oslo, Norway, 25 March 2026 - Zelluna ASA, a company pioneering allogeneic “off-the-shelf” T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, announces that the Board of Directors of Zelluna ASA has approved the Annual Report for 2025.  A PDF version of the Annual Report, as well as the report in European Single Electronic Format (ESEF), are attached to this release. The Annual Report is also available on the company's website: This information is subject to the disclosure requirements pursuant to Sectio...

 PRESS RELEASE

Zelluna inngår samarbeid med Etcembly for AI-drevet TCR-utvikling

Zelluna inngår samarbeid med Etcembly for AI-drevet TCR-utvikling Oslo, Norge, 9. mars 2026 – Zelluna (OSE: ZLNA) er et banebrytende selskap innen utvikling av allogene "off-the-shelf" T-cellereseptor-baserte naturlige dreperceller (TCR-NK) for behandling av solide kreftformer. Selskapet kunngjorde i dag et samarbeid med Etcembly Ltd, et bioteknologiselskap som anvender kunstig intelligens (AI) og avansert maskinlæring for optimalisering og utvikling av T-cellereseptorer (TCR). Høydepunkter: AI-drevet samarbeid for utvikling av KKLC1-rettede TCR-er til Zellunas TCR-NK-plattformBygger på v...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch